|
Dr. Bender has 25 years of experience in the pharmaceutical industry. Before joining Favrille, Dr. Bender was Director, Clinical Research-Oncology at Pfizer Global Research and Development (formerly Parke-Davis), where he was involved in the development of over 20 oncology and infectious disease compounds. During his career in the pharmaceutical industry, he submitted and defended the first industry-sponsored Orphan Drug Application for brain tumor drugs, and helped craft the final form of the Orphan Drug Regulations. He directed Parke-Davis's first clinical venture into the AIDS epidemic with an anti-folate, now successfully marketed for the treatment of Pneumocystis carinii pneumonia. Under his leadership, the drug was granted the first Treatment IND by the FDA. Dr. Bender was responsible for coordinating the world-wide development of a quinolone antibacterial for treatment of Mycobacterium avium intracellulare, and Mycobacterium tuberculosis with two other pharmaceutical companies, the World Health Organization and the Centers for Disease Control. | 